GENPREX INC (GNPX)
US3724462037 - Common Stock
GNPX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. While GNPX seems to be doing ok healthwise, there are quite some concerns on its profitability. GNPX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
GNPX had negative earnings in the past year.
In the past year GNPX has reported a negative cash flow from operations.
In the past 5 years GNPX always reported negative net income.
GNPX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GNPX has a Return On Assets of -581.22%. This is amonst the worse of the industry: GNPX underperforms 98.20% of its industry peers.
GNPX's Return On Equity of -1363.98% is on the low side compared to the rest of the industry. GNPX is outperformed by 83.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -581.22% | ||
| ROE | -1363.98% | ||
| ROIC | N/A |
ROA(3y)-144.02%
ROA(5y)-158.15%
ROE(3y)-190.93%
ROE(5y)-196.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GNPX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GNPX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GNPX has more shares outstanding
GNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -71.38, we must say that GNPX is in the distress zone and has some risk of bankruptcy.
GNPX has a worse Altman-Z score (-71.38) than 96.22% of its industry peers.
There is no outstanding debt for GNPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -71.38 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
GNPX has a Current Ratio of 0.86. This is a bad value and indicates that GNPX is not financially healthy enough and could expect problems in meeting its short term obligations.
GNPX's Current ratio of 0.86 is on the low side compared to the rest of the industry. GNPX is outperformed by 89.73% of its industry peers.
A Quick Ratio of 0.86 indicates that GNPX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.86, GNPX is doing worse than 88.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.86 |
3. Growth
3.1 Past
GNPX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.10%, which is quite impressive.
EPS 1Y (TTM)52.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, GNPX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.90% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y77.7%
EPS Next 2Y38.25%
EPS Next 3Y24.9%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GNPX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNPX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GNPX's earnings are expected to grow with 24.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.25%
EPS Next 3Y24.9%
5. Dividend
5.1 Amount
GNPX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENPREX INC
NASDAQ:GNPX (1/3/2025, 8:00:01 PM)
After market: 0.8624 +0.02 (+2.96%)0.8376
-0.06 (-7.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.46%
Inst Owner Change0%
Ins Owners1.38%
Ins Owner Change4.29%
Market Cap7.13M
Analysts82.5
Price Target8.93 (966.14%)
Short Float %7.64%
Short Ratio0.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.82%
Min EPS beat(2)-27.88%
Max EPS beat(2)37.52%
EPS beat(4)2
Avg EPS beat(4)-7.89%
Min EPS beat(4)-42.43%
Max EPS beat(4)37.52%
EPS beat(8)2
Avg EPS beat(8)-16.28%
EPS beat(12)4
Avg EPS beat(12)-12.35%
EPS beat(16)7
Avg EPS beat(16)-2.15%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)79.27%
EPS NY rev (1m)11.56%
EPS NY rev (3m)11.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-11.88
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-2.14
FCFYN/A
OCF(TTM)-2.14
OCFYN/A
SpS0
BVpS0.2
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -581.22% | ||
| ROE | -1363.98% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-144.02%
ROA(5y)-158.15%
ROE(3y)-190.93%
ROE(5y)-196.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 103.84% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z | -71.38 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)343.66%
Cap/Depr(5y)540%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.35%
EPS Next Y77.7%
EPS Next 2Y38.25%
EPS Next 3Y24.9%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.17%
OCF growth 3YN/A
OCF growth 5YN/A